Q4238 identifies Derm-Maxx, not Dermacyte. Select the product code that matches the material actually supplied rather than choosing by unit of measure.
On this page
CMS RVU26D · Effective 2026-10-01
Q4248 Wound allograft Medicare reimbursement rates in Kansas
Reports Dermacyte amniotic membrane allograft by square centimeter when supplied for application to a wound as part of a primary procedure. Compare Q4248 office and facility rates across CMS payment localities in Kansas.
Amounts below use the non-QP conversion factor for participating physicians. These are base physician payments before claim-level adjustments, not patient costs or total hospital charges.
What does Medicare pay for Q4248 in Kansas?
Kansas has 1 payment locality in this comparison. Use the service location to choose the applicable amount. These are the supported base rates for the payment area shown below, using the same CMS release.
Office / nonfacility
$115.04
1 of 1 localities have a supported rate.
Payment area: Kansas
One mapped payment locality.
Facility setting
No supported rate
These are locality ranges, not averages or address-specific quotes. A facility-setting amount covers the physician service; it does not include a hospital’s separate bill. Choose a locality below to inspect its calculation, compare other payment areas, or price a percentage of Medicare.
Wound care supplies
About Q4248: Dermacyte amniotic membrane allograft
Reports Dermacyte amniotic membrane allograft by square centimeter when supplied for application to a wound as part of a primary procedure.
Q4248 represents Dermacyte, an amniotic membrane allograft supplied by the square centimeter for wound care. A wound-care clinician, podiatrist, or surgeon may use the product on a prepared wound bed, including for a chronic ulcer such as a diabetic foot or venous leg ulcer. The product is reported separately from the work of applying it; the application procedure is selected for the wound site and treated area.
Report units that reflect the square centimeters of Dermacyte represented by the claim, and document the product, wound site, quantity used, and associated primary procedure. CMS classifies Q4248 as an add-on code: it must be billed with a primary procedure, and its payment falls within that procedure's global period. It is a technical-component-only code; a separate code covers interpretation, so Q4248 does not represent that professional service.
CMS billing rules for Q4248
- Global period
- Add-on code: billed only together with a primary procedure and paid within that procedure's global period.
- Professional and technical components
- Technical-component-only code: a separate code covers interpretation.
Where the value comes from
- Work RVU0.00 · 0%
- Practice expense (office) RVU3.81 · 100%
- Malpractice RVU0.00 · 0%
This summary was written with AI assistance from CMS physician fee schedule data and checked against the CMS billing rules shown here. Rates on this page come directly from CMS files.
Q4248 compared with similar codes
Office rates for Kansas, from the same CMS release.
Q4247 identifies an Amniotext patch product. Q4248 is specific to Dermacyte; the square-centimeter basis does not make the products interchangeable.
Q4249 identifies Amniply. Use Q4248 only when the product supplied is Dermacyte.
Compare Q4248 by payment locality
Find the payment area for your service address, then open its rate page for calculation inputs, release history and the percentage-of-Medicare tool. A city may cross payment-area boundaries; the ZIP lookup above helps resolve the location.
1 of 1 payment localities
Kansas →
Office / nonfacility
$115.04
Facility
Unavailable
Need rates for a whole code list?
Fee-sheet and API access are in early access. Tell us which codes and locations your team needs.
How this local rate is calculated
Each RVU component is multiplied by its own geographic practice cost index (GPCI). The three adjusted components are added, then multiplied by the conversion factor. These are the inputs used for Q4248 in Kansas.
PPRRVU2026_Oct_nonQPP.csv
18,336
- Code
- Q4248
- Physician work
- 0.00
- Practice expense
- 3.81
- Malpractice
- 0.00
GPCI2026.csv
54
- Locality
- Kansas
- Physician work
- 1.000
- Practice expense
- 0.904
- Malpractice
- 0.504
| Component | RVU | Locality factor | Adjusted |
|---|---|---|---|
| Physician work | 0.00 | × 1.000 | 0.0000 |
| Practice expense | 3.81 | × 0.904 | 3.4442 |
| Malpractice | 0.00 | × 0.504 | 0.0000 |
| Total RVUs | 3.4442 | ||
| Conversion factor | × 33.4009 | ||
Office / nonfacility rate, Kansas$115.04
Explore RVUs, geographic factors and the full formula
Office / nonfacility
| Component | RVU | Local GPCI |
|---|---|---|
| Work | 0 | 1 |
| Practice expense | 3.81 | 0.904 |
| Malpractice | 0 | 0.504 |
(0 × 1 + 3.81 × 0.904 + 0 × 0.504) × $33.4009 = $115.04
The office and facility calculations use their respective practice-expense RVUs. The facility amount here is the physician fee, not a separate hospital or facility bill.
Q4248 billing questions
Can Q4248 be billed by itself?
No. CMS identifies Q4248 as an add-on code that must be billed with a primary procedure.
How should units be reported?
Q4248 is measured per square centimeter. Document the Dermacyte quantity represented by the units on the claim.
Is the wound application included in Q4248?
Q4248 represents the Dermacyte product, not the application work. Report the appropriate primary application procedure with it.
Does Q4248 include professional interpretation?
No. CMS classifies it as technical-component-only and indicates that a separate code covers interpretation.
What documentation supports Q4248?
Record the product identity, wound site, square-centimeter quantity, and the associated primary procedure.
Where these rates come from
FeeBase calculates base physician payments from CMS work, practice-expense, and malpractice RVUs, adjusted by each locality’s geographic indices and the applicable conversion factor. Unavailable or separately priced services are labeled rather than assigned a made-up amount.
Source: RVU26D. Effective 2026-10-01 through the day before 2027-01-01.
